Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth.

Antibodies that neutralize (nAbs) genetically diverse HIV-1 strains have been recovered from a subset of HIV-1 infected subjects during chronic infection. Exact mechanisms that expand the otherwise narrow neutralization capacity observed during early infection are, however, currently undefined. Here...

Full description

Bibliographic Details
Main Authors: Megan K Murphy, Ling Yue, Ruimin Pan, Saikat Boliar, Anurag Sethi, Jianhui Tian, Katja Pfafferot, Etienne Karita, Susan A Allen, Emmanuel Cormier, Paul A Goepfert, Persephone Borrow, James E Robinson, S Gnanakaran, Eric Hunter, Xiang-Peng Kong, Cynthia A Derdeyn
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-02-01
Series:PLoS Pathogens
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23468623/pdf/?tool=EBI
id doaj-1edc3710ec2d4edda9d5d3b09d3a1741
record_format Article
spelling doaj-1edc3710ec2d4edda9d5d3b09d3a17412021-04-21T17:51:00ZengPublic Library of Science (PLoS)PLoS Pathogens1553-73661553-73742013-02-0192e100317310.1371/journal.ppat.1003173Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth.Megan K MurphyLing YueRuimin PanSaikat BoliarAnurag SethiJianhui TianKatja PfafferotEtienne KaritaSusan A AllenEmmanuel CormierPaul A GoepfertPersephone BorrowJames E RobinsonS GnanakaranEric HunterXiang-Peng KongCynthia A DerdeynAntibodies that neutralize (nAbs) genetically diverse HIV-1 strains have been recovered from a subset of HIV-1 infected subjects during chronic infection. Exact mechanisms that expand the otherwise narrow neutralization capacity observed during early infection are, however, currently undefined. Here we characterized the earliest nAb responses in a subtype A HIV-1 infected Rwandan seroconverter who later developed moderate cross-clade nAb breadth, using (i) envelope (Env) glycoproteins from the transmitted/founder virus and twenty longitudinal nAb escape variants, (ii) longitudinal autologous plasma, and (iii) autologous monoclonal antibodies (mAbs). Initially, nAbs targeted a single region of gp120, which flanked the V3 domain and involved the alpha2 helix. A single amino acid change at one of three positions in this region conferred early escape. One immunoglobulin heavy chain and two light chains recovered from autologous B cells comprised two mAbs, 19.3H-L1 and 19.3H-L3, which neutralized the founder Env along with one or three of the early escape variants carrying these mutations, respectively. Neither mAb neutralized later nAb escape or heterologous Envs. Crystal structures of the antigen-binding fragments (Fabs) revealed flat epitope contact surfaces, where minimal light chain mutation in 19.3H-L3 allowed for additional antigenic interactions. Resistance to mAb neutralization arose in later Envs through alteration of two glycans spatially adjacent to the initial escape signatures. The cross-neutralizing nAbs that ultimately developed failed to target any of the defined V3-proximal changes generated during the first year of infection in this subject. Our data demonstrate that this subject's first recognized nAb epitope elicited strain-specific mAbs, which incrementally acquired autologous breadth, and directed later B cell responses to target distinct portions of Env. This immune re-focusing could have triggered the evolution of cross-clade antibodies and suggests that exposure to a specific sequence of immune escape variants might promote broad humoral responses during HIV-1 infection.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23468623/pdf/?tool=EBI
collection DOAJ
language English
format Article
sources DOAJ
author Megan K Murphy
Ling Yue
Ruimin Pan
Saikat Boliar
Anurag Sethi
Jianhui Tian
Katja Pfafferot
Etienne Karita
Susan A Allen
Emmanuel Cormier
Paul A Goepfert
Persephone Borrow
James E Robinson
S Gnanakaran
Eric Hunter
Xiang-Peng Kong
Cynthia A Derdeyn
spellingShingle Megan K Murphy
Ling Yue
Ruimin Pan
Saikat Boliar
Anurag Sethi
Jianhui Tian
Katja Pfafferot
Etienne Karita
Susan A Allen
Emmanuel Cormier
Paul A Goepfert
Persephone Borrow
James E Robinson
S Gnanakaran
Eric Hunter
Xiang-Peng Kong
Cynthia A Derdeyn
Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth.
PLoS Pathogens
author_facet Megan K Murphy
Ling Yue
Ruimin Pan
Saikat Boliar
Anurag Sethi
Jianhui Tian
Katja Pfafferot
Etienne Karita
Susan A Allen
Emmanuel Cormier
Paul A Goepfert
Persephone Borrow
James E Robinson
S Gnanakaran
Eric Hunter
Xiang-Peng Kong
Cynthia A Derdeyn
author_sort Megan K Murphy
title Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth.
title_short Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth.
title_full Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth.
title_fullStr Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth.
title_full_unstemmed Viral escape from neutralizing antibodies in early subtype A HIV-1 infection drives an increase in autologous neutralization breadth.
title_sort viral escape from neutralizing antibodies in early subtype a hiv-1 infection drives an increase in autologous neutralization breadth.
publisher Public Library of Science (PLoS)
series PLoS Pathogens
issn 1553-7366
1553-7374
publishDate 2013-02-01
description Antibodies that neutralize (nAbs) genetically diverse HIV-1 strains have been recovered from a subset of HIV-1 infected subjects during chronic infection. Exact mechanisms that expand the otherwise narrow neutralization capacity observed during early infection are, however, currently undefined. Here we characterized the earliest nAb responses in a subtype A HIV-1 infected Rwandan seroconverter who later developed moderate cross-clade nAb breadth, using (i) envelope (Env) glycoproteins from the transmitted/founder virus and twenty longitudinal nAb escape variants, (ii) longitudinal autologous plasma, and (iii) autologous monoclonal antibodies (mAbs). Initially, nAbs targeted a single region of gp120, which flanked the V3 domain and involved the alpha2 helix. A single amino acid change at one of three positions in this region conferred early escape. One immunoglobulin heavy chain and two light chains recovered from autologous B cells comprised two mAbs, 19.3H-L1 and 19.3H-L3, which neutralized the founder Env along with one or three of the early escape variants carrying these mutations, respectively. Neither mAb neutralized later nAb escape or heterologous Envs. Crystal structures of the antigen-binding fragments (Fabs) revealed flat epitope contact surfaces, where minimal light chain mutation in 19.3H-L3 allowed for additional antigenic interactions. Resistance to mAb neutralization arose in later Envs through alteration of two glycans spatially adjacent to the initial escape signatures. The cross-neutralizing nAbs that ultimately developed failed to target any of the defined V3-proximal changes generated during the first year of infection in this subject. Our data demonstrate that this subject's first recognized nAb epitope elicited strain-specific mAbs, which incrementally acquired autologous breadth, and directed later B cell responses to target distinct portions of Env. This immune re-focusing could have triggered the evolution of cross-clade antibodies and suggests that exposure to a specific sequence of immune escape variants might promote broad humoral responses during HIV-1 infection.
url https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23468623/pdf/?tool=EBI
work_keys_str_mv AT megankmurphy viralescapefromneutralizingantibodiesinearlysubtypeahiv1infectiondrivesanincreaseinautologousneutralizationbreadth
AT lingyue viralescapefromneutralizingantibodiesinearlysubtypeahiv1infectiondrivesanincreaseinautologousneutralizationbreadth
AT ruiminpan viralescapefromneutralizingantibodiesinearlysubtypeahiv1infectiondrivesanincreaseinautologousneutralizationbreadth
AT saikatboliar viralescapefromneutralizingantibodiesinearlysubtypeahiv1infectiondrivesanincreaseinautologousneutralizationbreadth
AT anuragsethi viralescapefromneutralizingantibodiesinearlysubtypeahiv1infectiondrivesanincreaseinautologousneutralizationbreadth
AT jianhuitian viralescapefromneutralizingantibodiesinearlysubtypeahiv1infectiondrivesanincreaseinautologousneutralizationbreadth
AT katjapfafferot viralescapefromneutralizingantibodiesinearlysubtypeahiv1infectiondrivesanincreaseinautologousneutralizationbreadth
AT etiennekarita viralescapefromneutralizingantibodiesinearlysubtypeahiv1infectiondrivesanincreaseinautologousneutralizationbreadth
AT susanaallen viralescapefromneutralizingantibodiesinearlysubtypeahiv1infectiondrivesanincreaseinautologousneutralizationbreadth
AT emmanuelcormier viralescapefromneutralizingantibodiesinearlysubtypeahiv1infectiondrivesanincreaseinautologousneutralizationbreadth
AT paulagoepfert viralescapefromneutralizingantibodiesinearlysubtypeahiv1infectiondrivesanincreaseinautologousneutralizationbreadth
AT persephoneborrow viralescapefromneutralizingantibodiesinearlysubtypeahiv1infectiondrivesanincreaseinautologousneutralizationbreadth
AT jameserobinson viralescapefromneutralizingantibodiesinearlysubtypeahiv1infectiondrivesanincreaseinautologousneutralizationbreadth
AT sgnanakaran viralescapefromneutralizingantibodiesinearlysubtypeahiv1infectiondrivesanincreaseinautologousneutralizationbreadth
AT erichunter viralescapefromneutralizingantibodiesinearlysubtypeahiv1infectiondrivesanincreaseinautologousneutralizationbreadth
AT xiangpengkong viralescapefromneutralizingantibodiesinearlysubtypeahiv1infectiondrivesanincreaseinautologousneutralizationbreadth
AT cynthiaaderdeyn viralescapefromneutralizingantibodiesinearlysubtypeahiv1infectiondrivesanincreaseinautologousneutralizationbreadth
_version_ 1714665665602781184